Measurable residual disease testing in acute myeloid leukemia: current state, foundational models, and tools for future development

Cancer and Metastasis Reviews · Published 2026-03-27 · DOI 10.1007/s10555-026-10322-5

Free full text

Authors being retrieved — see the publisher record. https://doi.org/10.1007/s10555-026-10322-5

Abstract

PubPorta does not have an abstract for this article yet.

Read the article at the publisher →

Publication details

Year

2026

Related articles

• From bench to bedside: advancing our understanding of radioresistance in rectal cancer · Cancer and Metastasis Reviews · 2026 · Same journal
• Ferroptosis at the intersection of radiotherapy and immunotherapy · Cancer and Metastasis Reviews · 2025 · Same journal
• The link between microplastics and colorectal cancer · Cancer and Metastasis Reviews · 2026 · Same journal
• Tumor exosomes impact functional hallmarks of cancer · Cancer and Metastasis Reviews · 2026 · Same journal
• Combining radiotherapy and immune checkpoint inhibitors in metastatic cancers: a 25-year review of safety outcomes by the ENRSO Group · Cancer and Metastasis Reviews · 2025 · Same journal
• The immunobiology of pancreatic cancer metastasis: premetastatic niche formation, organ-specific immune landscapes, and therapeutic opportunities · Cancer and Metastasis Reviews · 2026 · Same journal
• Spatial omics: applications and utility in profiling the tumor microenvironment · Cancer and Metastasis Reviews · 2025 · Same journal
• Hyponatremia in cancer patients receiving immune checkpoint inhibitors: the ARON-MOUSEION-014 meta-analysis · Cancer and Metastasis Reviews · 2026 · Same journal
• Neuro-tumor interactions in peripheral tumors · Cancer and Metastasis Reviews · 2026 · Same journal
• One-carbon metabolism in cancer: moonlighting functions of metabolic enzymes and anti-tumor therapy · Cancer and Metastasis Reviews · 2025 · Same journal